Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TCM Biotech InternationalTPE:4169 -2.48%52 Cyclically Adjusted PS Ratio is 10.51 as of Aug. 10, 2026, which is 2% below its 10-year median of 10.68. GuruFocus rates TPE:4169 with a GF Score™ of 52/100 and a GF Value™ of NT$42.31 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 539 Biotechnology companies, TCM Biotech International ranks worse than 65.12% on this metric.
The historical rank and industry rank for TCM Biotech International's Cyclically Adjusted PS Ratio or its related term are showing as below:
TPE:4169'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.84 Med: 10.68 Max: 15.66
Current: 10.51
During the past 13 years, TCM Biotech International's highest Cyclically Adjusted PS Ratio was 15.66. The lowest was 3.84. And the median was 10.68.
TPE:4169's Cyclically Adjusted PS Ratio is ranked worse than 65.12% of 539
companies
in the Biotechnology industry
Industry Median: 5.71
vs TPE:4169: 10.51
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
TCM Biotech International's adjusted revenue per share data of for the fiscal year that ended in Dec25 was NT$11.605. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$14.94 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
TCM Biotech International (TPE:4169) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
TCM Biotech International Cyclically Adjusted PS Ratio Related Terms
TCM Biotech International Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for TCM Biotech International's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCM Biotech International Cyclically Adjusted PS Ratio Chart
TPE:4169 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, TCM Biotech International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TCM Biotech International Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TCM Biotech International's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where TCM Biotech International's Cyclically Adjusted PS Ratio falls into.
TCM Biotech International Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 10.51 mean?
TCM Biotech International (TPE:4169) has a Cyclically Adjusted PS Ratio of 10.51 as of Aug. 10, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on TCM Biotech International and its competitors. This is near median its historical median of 10.68. Over the past decade, TCM Biotech International's Cyclically Adjusted PS Ratio has ranged from 3.84 to 15.66. According to the industry distribution chart, TCM Biotech International ranks #351 out of 539 companies in the Biotechnology industry, placing it in the top 65.1%.
Is TCM Biotech International's Cyclically Adjusted PS Ratio too high?
TCM Biotech International's current Cyclically Adjusted PS Ratio of 10.51 is near median its 10-year median of 10.68. Over the past 10 years, this metric has ranged from a low of 3.84 to a high of 15.66. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.71. TCM Biotech International's value of 10.51 is 84.1% above this industry median. Based on the distribution chart, TCM Biotech International ranks #351 out of 539 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TCM Biotech International ranks #351 out of 539 companies for Cyclically Adjusted PS Ratio. This places TCM Biotech International in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.71. TCM Biotech International's value of 10.51 is 84.1% above this benchmark. Historically, TCM Biotech International's own Cyclically Adjusted PS Ratio has ranged from 3.84 to 15.66 over the past decade. While the company's 10-year median is 10.68 vs. the industry median of 5.71, TCM Biotech International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.71, based on 539 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TCM Biotech International's current Cyclically Adjusted PS Ratio of 10.51 is 84.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on TCM Biotech International and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TCM Biotech International's current Cyclically Adjusted PS Ratio is 10.51, which is near median its own 10-year median of 10.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$157.00 — trading 271.1% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 10.51, which is near median its 10-year median of 10.68 and 84.1% above the Biotechnology industry median of 5.71. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current Cyclically Adjusted PS Ratio is 10.51 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TCM Biotech International (TPE:4169) Overvalued in 2026?
Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued.
The current stock price of NT$157.00 is trading 271.1% above its estimated GF Value™ of NT$42.31.
GuruFocus considers TCM Biotech International to be Significantly Overvalued.
Key valuation signals for TPE:4169:
Cyclically Adjusted PS Ratio: 10.51 (near median its 10-year median of 10.68)
GF Value™: NT$42.31 vs. price of NT$157.00 (271.1% above fair value)
Industry Position: 84.1% above the Biotechnology median (#351 of 539)
No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score
Get the complete analysis for TPE:4169
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4169 has been successfully added to your 
